Chemical probes of Escherichia coli uncovered through chemical-chemical interaction profiling with compounds of known biological activity.
暂无分享,去创建一个
[1] K. Drlica,et al. DNA gyrase, topoisomerase IV, and the 4-quinolones , 1997, Microbiology and molecular biology reviews : MMBR.
[2] Steven D. Brown,et al. In vitro bactericidal activity of daptomycin against staphylococci. , 2002, The Journal of antimicrobial chemotherapy.
[3] Eric D Brown,et al. High-throughput screening of model bacteria. , 2009, Methods in molecular biology.
[4] H. Shapiro,et al. Correlation of Daptomycin Bactericidal Activity and Membrane Depolarization in Staphylococcus aureus , 2003, Antimicrobial Agents and Chemotherapy.
[5] B. Stockwell. Chemical genetics: ligand-based discovery of gene function , 2000, Nature Reviews Genetics.
[6] S. Cohen,et al. Analysis of gene control signals by DNA fusion and cloning in Escherichia coli. , 1980, Journal of molecular biology.
[7] K. Marotti,et al. The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin , 1997, Antimicrobial agents and chemotherapy.
[8] H. Schweizer. Triclosan: a widely used biocide and its link to antibiotics. , 2001, FEMS microbiology letters.
[9] T. Silhavy,et al. Genetic Basis for Activity Differences Between Vancomycin and Glycolipid Derivatives of Vancomycin , 2001, Science.
[10] Boris Hayete,et al. Gyrase inhibitors induce an oxidative damage cellular death pathway in Escherichia coli , 2007 .
[11] J. Lehár,et al. Multi-target therapeutics: when the whole is greater than the sum of the parts. , 2007, Drug discovery today.
[12] D. Feola,et al. Polymyxin B Sulfate and Colistin: Old Antibiotics for Emerging Multiresistant Gram-Negative Bacteria , 1999, The Annals of pharmacotherapy.
[13] B. Shoichet,et al. High-throughput assays for promiscuous inhibitors , 2005, Nature chemical biology.
[14] D. Bamford,et al. Stages of Polymyxin B Interaction with theEscherichia coli Cell Envelope , 2000, Antimicrobial Agents and Chemotherapy.
[15] L. Burdine,et al. Target identification in chemical genetics: the (often) missing link. , 2004, Chemistry & biology.
[16] I. Phillips,et al. The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates. , 2001, The Journal of antimicrobial chemotherapy.
[17] Michel Roberge,et al. Yeast genome-wide drug-induced haploinsufficiency screen to determine drug mode of action. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[18] Wolfgang Guba,et al. Development of a virtual screening method for identification of "frequent hitters" in compound libraries. , 2002, Journal of medicinal chemistry.
[19] Ryuta Kishii,et al. Target Preference of 15 Quinolones against Staphylococcus aureus, Based on Antibacterial Activities and Target Inhibition , 2001, Antimicrobial Agents and Chemotherapy.
[20] V. Lorian. Antibiotics in laboratory medicine , 2005 .
[21] Eric D Brown,et al. Are essential genes really essential? , 2009, Trends in microbiology.
[22] Sang Ho Lee,et al. A Staphylococcus aureus fitness test platform for mechanism-based profiling of antibacterial compounds. , 2009, Chemistry & biology.
[23] C H Wang,et al. Studies on the mechanism by which cyanine dyes measure membrane potential in red blood cells and phosphatidylcholine vesicles. , 1974, Biochemistry.
[24] Grant W. Brown,et al. Integration of chemical-genetic and genetic interaction data links bioactive compounds to cellular target pathways , 2004, Nature Biotechnology.
[25] J. C. Hinshaw,et al. Discovering Modes of Action for Therapeutic Compounds Using a Genome-Wide Screen of Yeast Heterozygotes , 2004, Cell.
[26] R. Kishony,et al. Functional classification of drugs by properties of their pairwise interactions , 2006, Nature Genetics.
[27] B. Shoichet,et al. Identification and prediction of promiscuous aggregating inhibitors among known drugs. , 2003, Journal of medicinal chemistry.
[28] Roy Kishony,et al. Networks from drug–drug surfaces , 2007, Molecular systems biology.
[29] Zemer Gitai,et al. MreB Actin-Mediated Segregation of a Specific Region of a Bacterial Chromosome , 2005, Cell.
[30] C. Walsh. Antibiotics: Actions, Origins, Resistance , 2003 .
[31] J. Heitman,et al. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast , 1991, Science.
[32] Corey Nislow,et al. Combination chemical genetics. , 2008, Nature chemical biology.
[33] Elizabeth A. Winzeler,et al. Genomic profiling of drug sensitivities via induced haploinsufficiency , 1999, Nature Genetics.
[34] J. Bartlett,et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[35] C. Kao,et al. Reverse engineering of industrial pharmaceutical-producing actinomycete strains using DNA microarrays. , 2004, Metabolic engineering.
[36] D. Botstein,et al. Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[37] J. Lehár,et al. High-order combination effects and biological robustness , 2008, Molecular systems biology.
[38] H. Giamarellou,et al. Multidrug-Resistant Gram-Negative Infections , 2009, Drugs.
[39] H. Neu,et al. Synergy of fosmidomycin (FR-31564) and other antimicrobial agents , 1982, Antimicrobial Agents and Chemotherapy.
[40] A. Barabasi,et al. Predicting synthetic rescues in metabolic networks , 2008, Molecular systems biology.
[41] Gary D Bader,et al. Systematic identification of protein complexes in Saccharomyces cerevisiae by mass spectrometry , 2002, Nature.
[42] E. Brown,et al. Multicopy suppressors for novel antibacterial compounds reveal targets and drug efflux susceptibility. , 2004, Chemistry & biology.
[43] B. Shoichet,et al. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. , 2002, Journal of medicinal chemistry.
[44] Gary D Bader,et al. Global Mapping of the Yeast Genetic Interaction Network , 2004, Science.
[45] E. Brown,et al. Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting. , 2009, Nature chemical biology.
[46] R. Moellering. Rationale for use of antimicrobial combinations. , 1983, The American journal of medicine.
[47] Robert P. St.Onge,et al. The Chemical Genomic Portrait of Yeast: Uncovering a Phenotype for All Genes , 2008, Science.
[48] A. Khodursky,et al. Topoisomerase IV is a target of quinolones in Escherichia coli. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[49] Peter J. Alaimo,et al. Chemical genetic approaches for the elucidation of signaling pathways. , 2001, Current opinion in chemical biology.
[50] Randall T Peterson,et al. Chemical biology and the limits of reductionism. , 2008, Nature chemical biology.
[51] K. Rand,et al. Reproducibility of the microdilution checkerboard method for antibiotic synergy , 1993, Antimicrobial Agents and Chemotherapy.
[52] Ajay,et al. Recognizing molecules with drug-like properties. , 1999, Current opinion in chemical biology.
[53] E. Brown,et al. High throughput screening identifies novel inhibitors of Escherichia coli dihydrofolate reductase that are competitive with dihydrofolate. , 2003, Bioorganic & medicinal chemistry letters.
[54] L. Kuyper,et al. Basis of selectivity of antibacterial diaminopyrimidines. , 1993, Journal of chemotherapy.